The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
FDA closes inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad with 2 observations
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
The investment in land is Rs. 19.85 crore
Subscribe To Our Newsletter & Stay Updated